Abstract
The use of rapamycin and thalidomide in a patient with metastatic gastroesophageal carcinoma, which led to disease stability associated with a significant tumor marker response and improved clinical quality of life, is reported.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Esophageal Neoplasms / drug therapy*
-
Esophagogastric Junction*
-
Humans
-
Male
-
Phosphorylation
-
Receptor, ErbB-2 / analysis
-
Sirolimus / administration & dosage
-
Stomach Neoplasms / drug therapy*
-
TOR Serine-Threonine Kinases / metabolism
-
Thalidomide / administration & dosage
Substances
-
Thalidomide
-
MTOR protein, human
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
TOR Serine-Threonine Kinases
-
Sirolimus